Published in Anticancer Res on November 10, 2006
Antiangiogenic drugs in ovarian cancer. Br J Cancer (2008) 1.06
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther (2014) 0.87
Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther (2013) 0.85
Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study. Br J Cancer (2008) 0.83
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol (2011) 0.79
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer. BMC Cancer (2010) 0.75
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol (2002) 2.27
SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res (2002) 2.09
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer (2010) 2.03
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab (2004) 1.75
The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol (2007) 1.61
Adjuvant treatment and survival in obese women with endometrial cancer: an international collaborative study. Am J Obstet Gynecol (2008) 1.52
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril (2002) 1.45
Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement. Int J Gynecol Cancer (2012) 1.45
Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract (2005) 1.43
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol (2010) 1.42
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol (2007) 1.40
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer (2004) 1.26
Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) (2007) 1.21
Genomic and non-genomic effects of estrogens on endothelial cells. Steroids (2004) 1.20
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
Null-type anaplastic lymphoma kinase-negative anaplastic large cell lymphoma arising in a silicone breast implant capsule. Plast Reconstr Surg (2011) 1.15
Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One (2008) 1.14
Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol (2005) 1.13
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol (2010) 1.12
Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol (2005) 1.12
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol (2004) 1.10
Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol (2007) 1.09
Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol (2011) 1.07
Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer (2009) 1.07
High diagnostic accuracy and interobserver reliability of real-time elastography in the evaluation of thyroid nodules. Ultrasound Med Biol (2012) 1.06
Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene (2003) 1.04
New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas (2005) 1.03
A mouse mammary tumor virus env-like exogenous sequence is strictly related to progression of human sporadic breast carcinoma. Am J Pathol (2011) 1.02
Genital and peritoneal tuberculosis: potential role of laparoscopy in diagnosis and management. J Am Assoc Gynecol Laparosc (2004) 1.02
Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert Opin Ther Targets (2013) 1.02
Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res (2009) 1.01
Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol (2007) 1.01
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas (2008) 1.00
High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab (2011) 1.00
Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecol Endocrinol (2012) 1.00
Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol (2006) 1.00
Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J (2010) 0.98
Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol (2005) 0.98
Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology (2010) 0.98
C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron (2002) 0.97
Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol (2009) 0.97
Primary lymphoma of the heart. A case report and review of the literature. Leuk Res (2002) 0.97
The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study. Eur Radiol (2009) 0.95
Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol (2009) 0.95
Fine-needle aspiration biopsy of the thyroid: comparison between thyroid palpation and ultrasonography. Endocr Pract (2002) 0.94
Surveillance procedures for patients treated for endometrial cancer: a review of the literature. Int J Gynecol Cancer (2010) 0.94
Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol (2008) 0.94
Severe aortic stenosis and myocardial function: diagnostic and prognostic usefulness of ultrasonic integrated backscatter analysis. Circulation (2004) 0.93
Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol (2010) 0.93
Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer (2007) 0.93
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol (2006) 0.93
Loss of nuclear p27(kip1) and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. Cancer Sci (2010) 0.92
Treatment options in recurrent cervical cancer (Review). Oncol Lett (2010) 0.92
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol (2004) 0.92
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer (2011) 0.91
Factors that influence Italian consumers' understanding of over-the-counter medicines and risk perception. Patient Educ Couns (2011) 0.90
Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol (2008) 0.90
Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol (2005) 0.90
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer (2012) 0.89
Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation. Thyroid (2010) 0.89
The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. Gynecol Oncol (2009) 0.89
Spontaneous cornual pregnancy after homolateral salpingectomy for an earlier tubal pregnancy: a case report and literature review. J Minim Invasive Gynecol (2009) 0.89
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect (2013) 0.88
Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol (2011) 0.88
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol (2006) 0.88
The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer (2014) 0.88
Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. Clin Endocrinol (Oxf) (2003) 0.87
Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitment. BMC Infect Dis (2010) 0.87
Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer (2008) 0.87
Assessment of swallowing by oropharyngoesophageal scintigraphy in patients with amyotrophic lateral sclerosis. Dysphagia (2006) 0.87
A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) (2004) 0.87
P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res (2006) 0.87
Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem (2008) 0.87